FindTrial
Sign In

tavokinogene telseplasmid

BIOLOGICAL3 trials

Sponsors

OncoSec Medical Incorporated, Chase Heaton, MD

Conditions

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III/IV MelanomaTriple Negative Breast CancerUnresectable Head and Neck Squamous Cell Carcinoma

Phase 2

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment
NCT03132675
OncoSec Medical IncorporatedStage III/IV Melanoma
Start: 2017-10-03End: 2024-07-31Target: 143Updated: 2023-03-27
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
NCT03567720
OncoSec Medical IncorporatedTriple Negative Breast Cancer
Start: 2018-10-11End: 2024-09-30Target: 65Updated: 2023-06-01
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
TerminatedNCT03823131
Chase Heaton, MDMetastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Start: 2019-05-02End: 2022-07-31Updated: 2023-05-09

Related Papers

Treatment of skin tumors with intratumoral interleukin 12 gene electrotransfer in the head and neck region: a first-in-human clinical trial protocol
Radiology and Oncology2022-05-1022 citations
Abstract OT2-01-03: Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO™) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-I141)
Cancer Research2022-02-152 citations
Abstract P2-14-06: Durable responses with intratumoral electroporation of plasmid interleukin-12 plus pembrolizumab in patients with advanced triple-negative breast cancer: Cohort 1 update from KEYNOTE-890
Cancer Research2022-02-15
383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695
Regular and Young Investigator Award Abstracts2021-11-013 citations
Trial in progress: A phase 2 study of intratumor pil-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV mealanoma progressing on either pembrolizumab or nivolumab treatment (PISCES).
Journal of Clinical Oncology2018-05-20